Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status is a research paper published in Journal for ImmunoTherapy of Cancer (2020). On theSindex it has a DataRank of 0.614. It has been cited 59 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.614
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: T32 CA009207
NCATS NIH HHS
Grant: UL1 TR002384
NHLBI NIH HHS
Grant: R01 HL111024
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R01 CA203636
NCI NIH HHS
Grant: U01 CA209414
NCI NIH HHS
Grant: R25 CA020449
FWCI
2.97
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals